database / hormone
Icatibant
also known as Firazyr
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 6918173. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.
A bradykinin B2 antagonist containing five non-proteinogenic residues.
Molecular data
| molecular formula | C59H89N19O13S |
|---|---|
| molecular weight | 1304.5 Da (PubChem) |
| computed backbone mass | not characterised |
| length | not characterised |
| net charge (pH 7.4) | not characterised |
| mean hydropathy | not characterised |
| half-life | not characterised |
| delivery route | subcutaneous |
| PubChem CID | 6918173 |
| PDB | not characterised |
| UniProt parent | not characterised |
Mechanism
Selective bradykinin B2 receptor antagonist.
Reported targets: BDKRB2
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| hereditary angioedema attack resolution in trials | Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary… The Journal of dermatology 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT04654351 | A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Here | COMPLETED | PHASE3 |
| NCT02826356 | Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema | COMPLETED | — |
| NCT04057131 | FIRAZYR General Drug Use-Results Survey (Japan) | COMPLETED | — |
| NCT04978051 | Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV- | COMPLETED | PHASE2 |
| NCT00965120 | The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway | COMPLETED | NA |
Literature (8)
Real-World Safety and Effectiveness of Icatibant in Patients With Hereditary Angioedema (HAE): Post-Marketing Surveillance in Japan — The Journal of dermatology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42630033 · DOI 10.1111/1346-8138.70447
Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review — Allergy and asthma proceedings 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42343494 · DOI 10.2500/aap.2026.47.260042
Overactivated bradykinin-B2 receptor promotes type a aortic dissection by inducing endothelial dysfunction: Therapeutic effect of icatibant — Life sciences 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42413717 · DOI 10.1016/j.lfs.2026.124572
On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation — Genes & diseases 2027
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42656409 · DOI 10.1016/j.gendis.2026.102233
Icatibant — National Institute of Child Health and Human Development, Bethesda (MD) 2006
No information is available on the excretion of icatibant into breastmilk. Because icatibant is a protein molecule with a molecular weight of 1305 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. One patient reportedly used the drug safely during breastfeeding. Waiting 6-12 hours after a dose before breastfeeding should minimize the amount of drug excreted into breastmilk.[1]
open access ↗ · PMID 36940272
Completion of the Icatibant Outcome Survey and What We Learned — Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
open access ↗ · PMID 41808316 · DOI 10.1111/cea.70271
Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure — Circulation. Heart failure 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42028604 · DOI 10.1161/circheartfailure.125.014117
Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells — Biomolecules 2025
MRGPRX2 (Mas-related G protein-coupled receptor member X2) is implicated in mast cell (MC)-driven disorders due to its ability to bind diverse ligands, which may be G-protein-biased or balanced, with the latter activating both G-proteins and the β-arrestin pathway. Icatibant, a peptide drug, produces injection-site reactions in most patients and is used experimentally to probe MRGPRX2 function in skin tests. While reported to be G-protein-biased, it is unknown how skin MCs respond to icatibant, although these are the primary target cells during therapy. We therefore compared responses to icatibant with those induced by the balanced agonist substance P (SP) in skin MCs. Degranulation and desensitization were assessed via β-hexosaminidase release, receptor internalization by flow cytometry, and downstream signaling by immunoblotting. Skin MCs degranulated in response to SP and icatibant, r…
open access ↗ · PMID 41008531 · DOI 10.3390/biom15091224
Related
Glucagon
hormone · 8 citations
Ghrelin
hormone · 8 citations
Oxytocin
hormone · 8 citations
Vasopressin
hormone · 8 citations
Gonadorelin
hormone · 8 citations
Kisspeptin-10
hormone · 8 citations